Shares of Vir Biotechnology (VIR), a clinical-stage biopharmaceutical company focused on infectious diseases and oncology, climbed almost 9% on Tuesday. This continued a broader upward trend that has seen the stock secure 11 gains in the previous 12 sessions The
Shares of Vir Biotechnology (VIR), a clinical-stage biopharmaceutical company focused on infectious diseases and oncology, climbed almost 9% on Tuesday.
This continued a broader upward trend that has seen the stock secure 11 gains in the previous 12 sessions
The
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.
